Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Stille ABOSTO:STIL -1.50%100 3-Year EBITDA Growth Rate is 13.00% as of Jun. 2026, which is 54% below its 10-year median of 28.20. GuruFocus rates OSTO:STIL with a GF Score™ of 100/100 and a GF Value™ of kr257.98 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 690 Medical Devices & Instruments companies, Stille AB ranks better than 55.22% on this metric.
During the past 12 months, Stille AB's average EBITDA Per Share Growth Rate was 25.40% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 13.00% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 31.40% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 14.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Stille AB was 141.70% per year. The lowest was -47.40% per year. And the median was 28.20% per year.
Stille AB (OSTO:STIL) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Stille AB 3-Year EBITDA Growth Rate Related Terms
OSTO:STIL vs ISRG, BDX, MDLN: 3-Year EBITDA Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, Stille AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stille AB 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Stille AB's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Stille AB's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 13.00% mean?
Stille AB (OSTO:STIL) has a 3-Year EBITDA Growth Rate of 13.00% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Stille AB and its competitors. This is 54% below median its historical median of 28.20. According to the industry distribution chart, Stille AB ranks #309 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 44.8%.
Is Stille AB's 3-Year EBITDA Growth Rate too high?
Stille AB's current 3-Year EBITDA Growth Rate of 13.00% is 54% below median its 10-year median of 28.20. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.35. Stille AB's value of 13.00% is 55.7% above this industry median. Based on the distribution chart, Stille AB ranks #309 out of 690 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Stille AB has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Stille AB's 3-Year EBITDA Growth Rate compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Stille AB ranks #309 out of 690 companies for 3-Year EBITDA Growth Rate. This puts Stille AB in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.35. Stille AB's value of 13.00% is 55.7% above this benchmark. While the company's 10-year median is 28.20 vs. the industry median of 8.35, Stille AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.35, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Stille AB's current 3-Year EBITDA Growth Rate of 13.00% is 55.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Stille AB and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stille AB's current 3-Year EBITDA Growth Rate is 13.00%, which is 54% below median its own 10-year median of 28.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stille AB stock overvalued right now?
Based on GuruFocus' analysis, Stille AB (OSTO:STIL) is currently considered Modestly Undervalued. The stock's GF Value™ is kr257.98, compared to a current price of kr230.00 — trading 10.8% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 13.00%, which is 54% below median its 10-year median of 28.20 and 55.7% above the Medical Devices & Instruments industry median of 8.35. Stille AB's overall GF Score™ is 100/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Stille AB (OSTO:STIL), the current 3-Year EBITDA Growth Rate is 13.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stille AB (OSTO:STIL) Overvalued in 2026?
Based on GuruFocus' analysis, Stille AB stock appears to be undervalued.
The current stock price of kr230.00 is trading 10.8% below its estimated GF Value™ of kr257.98.
GuruFocus considers Stille AB to be Modestly Undervalued.
Key valuation signals for OSTO:STIL:
3-Year EBITDA Growth Rate: 13.00% (54% below median its 10-year median of 28.20)
GF Value™: kr257.98 vs. price of kr230.00 (10.8% below fair value)
Industry Position: 55.7% above the Medical Devices & Instruments median (#309 of 690)
No single metric tells the full story. See the OSTO:STIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stille AB manufactures and distributes medical devices. Its products include surgical equipment such as Surgical Scissors, Forceps, Curettes, Raspatories, Elevators, c-arm tables and instrument care education, among others.
100GF Score
Get the complete analysis for OSTO:STIL
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:STIL has been successfully added to your 
